ArticleCell reports2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters.Frontiers in immunology · 2025Article
- Article
- Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity.Nature communications · 2024Article
- Enhanced detection of antigen-specific T cells by a multiplexed AIM assay.Cell reports methods · 2024Article
- Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4Cell host & microbe · 2023Article
- Article
- Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine.Cell reports · 2023Article
- An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells.iScience · 2023Article
- SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.Frontiers in immunology · 2023Article
- A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.Cell reports · 2022Article
- Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition.Vaccines · 2022Article
- Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients.iScience · 2022Article
- Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2.Frontiers in immunology · 2022Review
Corrections and comments
- Update of
Authors and funding
33 authors at 3 institutions in 1 country.
Manon NayracCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Mathieu DubéCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Gérémy SannierCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Alexandre NicolasCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Lorie MarchittoCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Olivier TastetCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Alexandra TauzinCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Nathalie BrassardCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Raphaël Lima-BarbosaUniversité de Montréal, Montréal, QC H3T 1J4, Canada.
Guillaume Beaudoin-BussièresCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Dani VézinaCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Shang Yu GongCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC H3A 2B4, Canada.
Mehdi BenlarbiCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Romain GasserCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Annemarie LaumaeaCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Jérémie PrévostCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Catherine BourassaCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Gabrielle Gendron-LepageCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Halima MedjahedCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Guillaume GoyetteCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Gloria-Gabrielle Ortega-DelgadoCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Mélanie LaporteCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Julia NiesslCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Laurie GokoolCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Chantal MorrisseauCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Pascale ArlottoCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Jonathan RichardCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Justin BélairUniversité de Montréal, Montréal, QC H3T 1J4, Canada.
Alexandre PratCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Départment of Neurosciences, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
Cécile TremblayCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Valérie Martel-LaferrièreCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada.
Andrés FinziCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC H3A 2B4, Canada. Electronic address: andres.finzi@umontreal.ca.
Daniel E KaufmannCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada; Département de Médecine, Université de Montréal, Montréal, QC H3T 1J4, Canada. Electronic address: daniel.kaufmann@umontreal.ca.
Centre Hospitalier de l’Université de Montréal · CAUniversité de Montréal · CAMcGill University Health Centre · CA
Funding
CIHR 177958CIHR 178344CIHR 352417
Abstract
Spacing of BNT162b2 mRNA doses beyond 3 weeks raises concerns about vaccine efficacy. We longitudinally analyze B cell, T cell, and humoral responses to two BNT162b2 mRNA doses administered 16 weeks apart in 53 SARS-CoV-2 naive and previously infected donors. This regimen elicits robust RBD-specific B cell responses whose kinetics differs between cohorts, the second dose leading to increased magnitude in naive participants only. While boosting does not increase magnitude of CD4
Indexed as
COVID-19Viral VaccinesAntibodies, ViralBNT162 VaccineHumansImmunity, HumoralRNA, MessengerSARS-CoV-2Antibodies, ViralBNT162 VaccineRNA, MessengerViral VaccinesAIM assayB cellsCD4 T cellCD4 T cell helpCD8 T cellcoronavirusCOVID-19CP: Immunologyhumoral responsesimmunological memorylonger intervalmRNA vaccineSARS-CoV-2Spike glycoproteinsvaccine regimen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.